The Way Forward: Practical Clinical Considerations for the Use of Canakinumab in Patients With Difficult-to-Treat Gouty Arthritis - 22/12/15
Abstract |
Canakinumab is indicated for patients with frequent gouty arthritis attacks who cannot be managed with standard-of-care medication, and should be used according to the labeled indication. Given its mechanism of action, physicians need to be aware of the potential contraindications and precautions with its use. When deciding as to whether a patient with gouty arthritis is an appropriate candidate for canakinumab treatment, several key clinical considerations should be kept in mind, which are discussed herein.
Le texte complet de cet article est disponible en PDF.Keywords : Canakinumab, Difficult-to-treat gouty arthritis, Interleukin (IL)-1β inhibitor, Monosodium urate crystals, Urate-lowering therapy
Vol 82 - N° S1
P. eS30-eS32 - octobre 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?